The aminoglycoside-modifying enzyme Eis2 represents a new potential in vivo target for reducing antimicrobial drug resistance in Mycobacterium abscessus complex

Eur Respir J. 2022 Dec 1;60(6):2201541. doi: 10.1183/13993003.01541-2022. Print 2022 Dec.

Authors

Nicola Ivan Lorè¹, Fabio Saliu², Andrea Spitaleri², Daniel Schäfle³, Francesca Nicola², Daniela Maria Cirillo^{2

4}, Peter Sander^{3

5

4}

Affiliations

¹ Emerging Bacterial Pathogens Unit, DITID-IRCCS Ospedale San Raffaele, Milan, Italy lore.nicolaivan@hsr.it.
² Emerging Bacterial Pathogens Unit, DITID-IRCCS Ospedale San Raffaele, Milan, Italy.
³ Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
⁴ P. Sander and D.M. Cirillo have contributed equally to this article as co-last authors and supervised the work.
⁵ National Center for Mycobacteria, Zurich, Switzerland.

PMID: 36265879
DOI: 10.1183/13993003.01541-2022

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aminoglycosides / pharmacology
Aminoglycosides / therapeutic use
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Drug Resistance, Bacterial
Drug Resistance, Microbial
Humans
Microbial Sensitivity Tests
Mycobacterium Infections, Nontuberculous* / drug therapy
Mycobacterium Infections, Nontuberculous* / microbiology
Mycobacterium abscessus*

Substances

Aminoglycosides
Anti-Bacterial Agents